Moreover, EGFR kinases inhibitors used as cancer therapy such as Erlotinib, Lapatinib and monoclonal antibodies targeting the extracellular domain of EGFR including Cetuximab were shown to improve psoriatic lesions in cancer patients (46–50). The gene discussed is EGFR; the disease is cancer.